Preoperative chemotherapy could modify recurrence patterns through postoperative complications in patients with gastric cancer.
Postoperative complication
Preoperative chemotherapy
Recurrence pattern
Stomach neoplasm
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
14
11
2020
accepted:
16
03
2021
pubmed:
22
3
2021
medline:
25
9
2021
entrez:
21
3
2021
Statut:
ppublish
Résumé
Postoperative infectious complications have a negative impact on survival outcomes in patients with gastric cancer. It is recently reported that preoperative chemotherapy may eliminate this negative impact. This study aimed to confirm whether preoperative chemotherapy can eliminate the negative impact of postoperative infectious complications (IC) on survival outcomes and elucidate the association between postoperative infectious complications and recurrence patterns. We retrospectively reviewed data of 86 patients who received preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by R0 gastrectomy at the Kitasato University between 2006 and 2016. Patients who developed grade II or higher infectious complications during hospitalization were grouped into the IC group, while others were grouped into the non-IC (NIC) group. Survival outcomes and recurrence patterns were analyzed between the two groups. Infectious complications with Clavien-Dindo classification of grade II or higher were found in 12 patients (14.0%, IC group). The median observational period was 61 months. Overall survival and progression-free survival were similar in the IC and NIC groups. Recurrence occurred in 39 patients. The proportions of peritoneal and lymph node recurrences were not significantly different between the two groups. However, the proportion of distant metastasis in the IC group was significantly higher than that in NIC group (3/4 [75%] vs. 9/35 [17%], p = 0.04). Pathological stage after neoadjuvant therapy plays a stronger role in recurrence than postoperative complications. Lymph node and peritoneal metastasis may be suppressed by preoperative chemotherapy.
Identifiants
pubmed: 33745003
doi: 10.1007/s00423-021-02153-5
pii: 10.1007/s00423-021-02153-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1045-1055Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
pubmed: 30207593
Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M (2013) Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol 20:1575–1583. https://doi.org/10.1245/s10434-012-2720-9
doi: 10.1245/s10434-012-2720-9
pubmed: 23076557
Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, Aikou S, Watanabe R, Kosuga T, Yamaguchi T (2014) Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol 21:891–898. https://doi.org/10.1245/s10434-013-3384-9
doi: 10.1245/s10434-013-3384-9
pubmed: 24254205
Bell SW, Walker KG, Rickard MJFX, Sinclair G, Dent OF, Chapuis PH, Bokey EL (2003) Anastomotic leakage after curative anterior resection results in a higher prevalence of local recurrence. Br J Surg 90:1261–1266. https://doi.org/10.1002/bjs.4219
doi: 10.1002/bjs.4219
pubmed: 14515297
Law WL, Choi HK, Lee YM, Ho JWC, Seto CL (2007) Anastomotic leakage is associated with poor long-term outcome in patients after curative colorectal resection for malignancy. J Gastrointest Surg 11:8–15. https://doi.org/10.1007/s11605-006-0049-z
doi: 10.1007/s11605-006-0049-z
pubmed: 17390180
Booka E, Takeuchi H, Nishi T, Matsuda S, Kaburagi T, Fukuda K, Nakamura R, Takahashi T, Wada N, Kawakubo H, Omori T, Kitagawa Y (2015) The impact of postoperative complications on survivals after esophagectomy for esophageal cancer. Med (United States) 94:e1369. https://doi.org/10.1097/MD.0000000000001369
doi: 10.1097/MD.0000000000001369
Kataoka K, Takeuchi H, Mizusawa J, Igaki H, Ozawa S, Abe T, Nakamura K, Kato K, Ando N, Kitagawa Y (2017) Prognostic impact of postoperative morbidity after esophagectomy for esophageal cancer: exploratory analysis of JCOG9907. Ann Surg 265:1152–1157. https://doi.org/10.1097/SLA.0000000000001828
doi: 10.1097/SLA.0000000000001828
pubmed: 27280509
Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M (2019) Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol 37:1296–1304. https://doi.org/10.1200/JCO.18.01138
doi: 10.1200/JCO.18.01138
pubmed: 30925125
pmcid: 6524985
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820. https://doi.org/10.1056/NEJMoa072252
doi: 10.1056/NEJMoa072252
pubmed: 17978289
Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra. Lancet 393:1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1
doi: 10.1016/S0140-6736(18)32557-1
pubmed: 30982686
pmcid: 30982686
Tokunaga M, Mizusawa J, Machida N, Fukagawa T, Katai H, Nishida Y, Yabusaki H, Ito S, Sano T, Sasako M, Boku N, Yoshikawa T, Katayama H, Fukuda H, Terashima M (2017) Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA trial). J Clin Oncol 35:TPS4134–TPS4134. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS4134
doi: 10.1200/JCO.2017.35.15_suppl.TPS4134
Hayashi M, Yoshikawa T, Yura M, Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T (2019) Does neoadjuvant chemotherapy cancel out the negative survival impact induced by surgical complications after gastrectomy? Gastric Cancer 22:1274–1284. https://doi.org/10.1007/s10120-019-00957-5
doi: 10.1007/s10120-019-00957-5
pubmed: 30945120
Eto K, Hiki N, Kumagai K, Shoji Y, Tsuda Y, Kano Y, Yasufuku I, Okumura Y, Tsujiura M, Ida S, Nunobe S, Ohashi M, Sano T, Yamaguchi T (2018) Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer 21:703–709. https://doi.org/10.1007/s10120-017-0781-y
doi: 10.1007/s10120-017-0781-y
pubmed: 29188456
Hosoda K, Azuma M, Katada C, Moriya H, Mieno H, Ishido K, Ema A, Ushiku H, Wada T, Washio M, Watanabe A, Higuchi K, Tanabe S, Koizumi W, Watanabe M, Yamashita K (2018) A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. Gastric Cancer 22:598–606. https://doi.org/10.1007/s10120-018-0884-0
doi: 10.1007/s10120-018-0884-0
pubmed: 30284080
Hosoda K, Katada C, Ishido K, Niihara M, Ushiku H, Sakuraya M, Washio M, Wada T, Watanabe A, Harada H, Sato T, Tajima H, Kaizu T, Kosaka Y, Kato H, Sengoku N, Tanaka K, Naito T, Kumamoto Y, Sangai T, Tanabe S, Koizumi W, Yamashita K, Hiki N (2020) Neoadjuvant chemotherapy plus surgery for high-risk advanced gastric cancer: long-term results of KDOG1001 trial. Langenbeck's Arch Surg 405:777–785. https://doi.org/10.1007/s00423-020-01924-w
doi: 10.1007/s00423-020-01924-w
Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, Takagi S, Azuma M, Ae T, Ishido K, Nakatani K, Naruke A, Katada C (2012) A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol 69:407–413. https://doi.org/10.1007/s00280-011-1701-1
doi: 10.1007/s00280-011-1701-1
pubmed: 21796483
Mieno H, Yamashita K, Hosoda K et al (2017) Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. Surg Today 47. https://doi.org/10.1007/s00595-017-1512-z
Sano T, Kodera Y (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112. https://doi.org/10.1007/s10120-011-0041-5
doi: 10.1007/s10120-011-0041-5
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 1360123
pmcid: 1360123
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196. https://doi.org/10.1097/SLA.0b013e3181b13ca2
doi: 10.1097/SLA.0b013e3181b13ca2
pubmed: 19638912
pmcid: 19638912
McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12:223–226. https://doi.org/10.1097/MCO.0b013e32832a7902
doi: 10.1097/MCO.0b013e32832a7902
pubmed: 19318937
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. https://doi.org/10.1038/nature07205
doi: 10.1038/nature07205
pubmed: 18650914
Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A (2017) Natural killer cell response to chemotherapy-stressed cancer cells: role in tumor immunosurveillance. Front Immunol:8. https://doi.org/10.3389/fimmu.2017.01194
Ma X, Zhang C, Wang C, Miao W, Zhou W, An J, Qiao W, Li M, Lai M, Yu P (2020) Comparison of clinicopathologic profiles and prognosis of gastric cancer in the upper, middle and lower third of the stomach: a retrospective cohort study. Medicine (Baltimore) 99:e21261. https://doi.org/10.1097/MD.0000000000021261
doi: 10.1097/MD.0000000000021261
Wang X, Liu F, Li Y, Tang S, Zhang Y, Chen Y, Khan SA (2019) Comparison on clinicopathological features, treatments and prognosis between proximal gastric cancer and distal gastric cancer: a national cancer data base analysis. J Cancer 10:3145–3153. https://doi.org/10.7150/jca.30371
doi: 10.7150/jca.30371
pubmed: 31289585
pmcid: 6603385
Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Nashimoto A, Ito S, Kaji M, Imamura H, Fukushima N, Fujitani K, Stomach Cancer Study Group of the Japan Clinical Oncology Group (2017) Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg 265:277–283. https://doi.org/10.1097/SLA.0000000000001814
doi: 10.1097/SLA.0000000000001814
pubmed: 27280511
Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M (2014) Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 101:653–660. https://doi.org/10.1002/bjs.9484
doi: 10.1002/bjs.9484
pubmed: 24668391
Iwasaki Y, Sasako M, Yamamoto S, Nakamura K, Sano T, Katai H, Tsujinaka T, Nashimoto A, Fukushima N, Tsuburaya A, on behalf of the Gastric Cancer Surgical Study Group of the Japan Clinical Oncology Group (2013) Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol 107:741–745. https://doi.org/10.1002/jso.23301
doi: 10.1002/jso.23301
pubmed: 23400787
Terashima M, Iwasaki Y, Mizusawa J et al (2019) Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer 22:1044–1052. https://doi.org/10.1007/s10120-019-00941-z
doi: 10.1007/s10120-019-00941-z
pubmed: 30827001